Literature DB >> 2253556

Physiological disposition of HMG-CoA-reductase inhibitors.

D E Duggan1, S Vickers.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2253556     DOI： 10.3109/03602539009041088

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN： 0360-2532            Impact factor:   4.518


× No keyword cloud information.
  16 in total

1.  Comparison of in vitro hepatic models for the prediction of metabolic interaction between simvastatin and naringenin.

Authors:  N Le Goff; J C Koffel; S Vandenschrieck; L Jung; G Ubeaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

2.  Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin.

Authors:  H Cheng; J D Rogers; A E Sweany; M R Dobrinska; E A Stein; A C Tate; R D Amin; H Quan
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

3.  Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations.

Authors:  G E Gutierrez; D Lalka; I R Garrett; G Rossini; G R Mundy
Journal:  Osteoporos Int       Date:  2006-05-03       Impact factor: 4.507

Review 4.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

5.  Statins repress hedgehog signaling in medulloblastoma with no bone toxicities.

Authors:  Qianhai Fan; Tingting Gong; Chaonan Zheng; Jessica M Y Ng; Jianquan Chen; Cynthia Myers; Harvey Hensley; Tom Curran; Zeng-Jie Yang
Journal:  Oncogene       Date:  2021-03-01       Impact factor: 9.867

Review 6.  The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.

Authors:  Iain P Hargreaves; Andrew J Duncan; Simon J R Heales; John M Land
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 7.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Statins inhibit lymphocyte homing to peripheral lymph nodes.

Authors:  René Schramm; Michael D Menger; Yves Harder; Rudolf Schmits; Oliver Adam; Gabriele Weitz-Schmidt; Hans-Joachim Schäfers
Journal:  Immunology       Date:  2006-11-28       Impact factor: 7.397

Review 9.  Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Authors:  H Lennernäs; G Fager
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

Review 10.  Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.

Authors:  Jonathan Wagner; J Steven Leeder
Journal:  Pediatr Clin North Am       Date:  2012-08-22       Impact factor: 3.278
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.